Cargando…

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

INTRODUCTION: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs). METHODS: We conducted a multicenter retrospective study analyzing the data of 308 patients with met...

Descripción completa

Detalles Bibliográficos
Autores principales: Ünal, Çağlar, Azizy, Abdulmunir, Karabulut, Senem, Taştekin, Didem, Akyıldız, Arif, Yaşar, Serkan, Yalçın, Şuayib, Çoban, Eyüp, Evrensel, Türkkan, Kalkan, Ziya, Oruç, Zeynep, Derin, Sümeyra, Turna, Zeynep Hande, Bayram, Doğan, Köş, Fahriye Tuğba, Şendur, Mehmet Ali Nihat, Sever, Nadiye, Ercelep, Özlem, Seyyar, Mustafa, Kefeli, Umut, Uygun, Kazım, Özçelik, Melike, Ön, Sercan, Şanlı, Ulus Ali, Canaslan, Kübra, Ünek, İlkay Tuba, Yücel, Kadriye Bir, Özdemir, Nuriye, Yazıcı, Ozan, Güzel, Halil Göksel, Salim, Derya Kıvrak, Göksu, Sema Sezgin, Tatlı, Ali Murat, Ordu, Çetin, Selvi, Oğuzhan, Sakin, Abdullah, Büyükbayram, Mehmet Emin, Dursun, Bengü, Ürün, Yüksel, Arak, Hacı, Ağdaş, Gözde, Uğraklı, Muzaffer, Hendem, Engin, Eryılmaz, Melek Karakurt, Bilgin, Burak, Topçu, Atakan, Şimşek, Melih, Büyükşimşek, Mahmut, Akay, Büşra, Erdal, Gülçin Şahingöz, Karataş, Fatih, Alan, Özkan, Çağlayan, Melek, Kahvecioğlu, Fatma Akdağ, Demirci, Ayşe, Paksoy, Nail, Çetin, Bülent, Gümüş, Mahmut, Ak, Naziye, Aydınalp, Yasemin, Paydaş, Semra, Güven, Deniz Can, Kılıçkap, Saadettin, Sağlam, Sezer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546829/
https://www.ncbi.nlm.nih.gov/pubmed/37676712
http://dx.doi.org/10.1093/oncolo/oyad257
_version_ 1785114941123985408
author Ünal, Çağlar
Azizy, Abdulmunir
Karabulut, Senem
Taştekin, Didem
Akyıldız, Arif
Yaşar, Serkan
Yalçın, Şuayib
Çoban, Eyüp
Evrensel, Türkkan
Kalkan, Ziya
Oruç, Zeynep
Derin, Sümeyra
Turna, Zeynep Hande
Bayram, Doğan
Köş, Fahriye Tuğba
Şendur, Mehmet Ali Nihat
Sever, Nadiye
Ercelep, Özlem
Seyyar, Mustafa
Kefeli, Umut
Uygun, Kazım
Özçelik, Melike
Ön, Sercan
Şanlı, Ulus Ali
Canaslan, Kübra
Ünek, İlkay Tuba
Yücel, Kadriye Bir
Özdemir, Nuriye
Yazıcı, Ozan
Güzel, Halil Göksel
Salim, Derya Kıvrak
Göksu, Sema Sezgin
Tatlı, Ali Murat
Ordu, Çetin
Selvi, Oğuzhan
Sakin, Abdullah
Büyükbayram, Mehmet Emin
Dursun, Bengü
Ürün, Yüksel
Arak, Hacı
Ağdaş, Gözde
Uğraklı, Muzaffer
Hendem, Engin
Eryılmaz, Melek Karakurt
Bilgin, Burak
Topçu, Atakan
Şimşek, Melih
Büyükşimşek, Mahmut
Akay, Büşra
Erdal, Gülçin Şahingöz
Karataş, Fatih
Alan, Özkan
Çağlayan, Melek
Kahvecioğlu, Fatma Akdağ
Demirci, Ayşe
Paksoy, Nail
Çetin, Bülent
Gümüş, Mahmut
Ak, Naziye
Aydınalp, Yasemin
Paydaş, Semra
Güven, Deniz Can
Kılıçkap, Saadettin
Sağlam, Sezer
author_facet Ünal, Çağlar
Azizy, Abdulmunir
Karabulut, Senem
Taştekin, Didem
Akyıldız, Arif
Yaşar, Serkan
Yalçın, Şuayib
Çoban, Eyüp
Evrensel, Türkkan
Kalkan, Ziya
Oruç, Zeynep
Derin, Sümeyra
Turna, Zeynep Hande
Bayram, Doğan
Köş, Fahriye Tuğba
Şendur, Mehmet Ali Nihat
Sever, Nadiye
Ercelep, Özlem
Seyyar, Mustafa
Kefeli, Umut
Uygun, Kazım
Özçelik, Melike
Ön, Sercan
Şanlı, Ulus Ali
Canaslan, Kübra
Ünek, İlkay Tuba
Yücel, Kadriye Bir
Özdemir, Nuriye
Yazıcı, Ozan
Güzel, Halil Göksel
Salim, Derya Kıvrak
Göksu, Sema Sezgin
Tatlı, Ali Murat
Ordu, Çetin
Selvi, Oğuzhan
Sakin, Abdullah
Büyükbayram, Mehmet Emin
Dursun, Bengü
Ürün, Yüksel
Arak, Hacı
Ağdaş, Gözde
Uğraklı, Muzaffer
Hendem, Engin
Eryılmaz, Melek Karakurt
Bilgin, Burak
Topçu, Atakan
Şimşek, Melih
Büyükşimşek, Mahmut
Akay, Büşra
Erdal, Gülçin Şahingöz
Karataş, Fatih
Alan, Özkan
Çağlayan, Melek
Kahvecioğlu, Fatma Akdağ
Demirci, Ayşe
Paksoy, Nail
Çetin, Bülent
Gümüş, Mahmut
Ak, Naziye
Aydınalp, Yasemin
Paydaş, Semra
Güven, Deniz Can
Kılıçkap, Saadettin
Sağlam, Sezer
author_sort Ünal, Çağlar
collection PubMed
description INTRODUCTION: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs). METHODS: We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions of Turkey. RESULTS: The median follow-up time was 41.0 months (range: 1.7-212.1), and the median age was 53 years (range: 22-79). Our results across the entire patient cohort showed a median progression-free survival (PFS) of 10.6 months and a median overall survival (OS) of 60.4 months. First-line CAPTEM treatment appeared more effective, with a median PFS of 16.1 months and a median OS of 105.8 months (median PFS 16.1, 7.9, and 9.6 months in first-, second- and ≥third-line respectively, P = .01; with median OS values of 105.8, 47.2, and 24.1 months, respectively, P = .003) In terms of ORR, the first-line treatment again performed better, resulting in an ORR of 54.7% compared to 33.3% and 30.0% in the second and third or higher lines, respectively (P < .001). Grade 3-4 side effects occurred only in 22.5% of the patients, leading to a discontinuation rate of 9.5%. Despite the differences in outcomes based on treatment line, we did not observe a significant difference in terms of side effects between the first and subsequent lines of treatment. CONCLUSIONS AND RELEVANCE: The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET.
format Online
Article
Text
id pubmed-10546829
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105468292023-10-04 Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group Ünal, Çağlar Azizy, Abdulmunir Karabulut, Senem Taştekin, Didem Akyıldız, Arif Yaşar, Serkan Yalçın, Şuayib Çoban, Eyüp Evrensel, Türkkan Kalkan, Ziya Oruç, Zeynep Derin, Sümeyra Turna, Zeynep Hande Bayram, Doğan Köş, Fahriye Tuğba Şendur, Mehmet Ali Nihat Sever, Nadiye Ercelep, Özlem Seyyar, Mustafa Kefeli, Umut Uygun, Kazım Özçelik, Melike Ön, Sercan Şanlı, Ulus Ali Canaslan, Kübra Ünek, İlkay Tuba Yücel, Kadriye Bir Özdemir, Nuriye Yazıcı, Ozan Güzel, Halil Göksel Salim, Derya Kıvrak Göksu, Sema Sezgin Tatlı, Ali Murat Ordu, Çetin Selvi, Oğuzhan Sakin, Abdullah Büyükbayram, Mehmet Emin Dursun, Bengü Ürün, Yüksel Arak, Hacı Ağdaş, Gözde Uğraklı, Muzaffer Hendem, Engin Eryılmaz, Melek Karakurt Bilgin, Burak Topçu, Atakan Şimşek, Melih Büyükşimşek, Mahmut Akay, Büşra Erdal, Gülçin Şahingöz Karataş, Fatih Alan, Özkan Çağlayan, Melek Kahvecioğlu, Fatma Akdağ Demirci, Ayşe Paksoy, Nail Çetin, Bülent Gümüş, Mahmut Ak, Naziye Aydınalp, Yasemin Paydaş, Semra Güven, Deniz Can Kılıçkap, Saadettin Sağlam, Sezer Oncologist Endocrinology INTRODUCTION: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs). METHODS: We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions of Turkey. RESULTS: The median follow-up time was 41.0 months (range: 1.7-212.1), and the median age was 53 years (range: 22-79). Our results across the entire patient cohort showed a median progression-free survival (PFS) of 10.6 months and a median overall survival (OS) of 60.4 months. First-line CAPTEM treatment appeared more effective, with a median PFS of 16.1 months and a median OS of 105.8 months (median PFS 16.1, 7.9, and 9.6 months in first-, second- and ≥third-line respectively, P = .01; with median OS values of 105.8, 47.2, and 24.1 months, respectively, P = .003) In terms of ORR, the first-line treatment again performed better, resulting in an ORR of 54.7% compared to 33.3% and 30.0% in the second and third or higher lines, respectively (P < .001). Grade 3-4 side effects occurred only in 22.5% of the patients, leading to a discontinuation rate of 9.5%. Despite the differences in outcomes based on treatment line, we did not observe a significant difference in terms of side effects between the first and subsequent lines of treatment. CONCLUSIONS AND RELEVANCE: The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET. Oxford University Press 2023-09-07 /pmc/articles/PMC10546829/ /pubmed/37676712 http://dx.doi.org/10.1093/oncolo/oyad257 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Endocrinology
Ünal, Çağlar
Azizy, Abdulmunir
Karabulut, Senem
Taştekin, Didem
Akyıldız, Arif
Yaşar, Serkan
Yalçın, Şuayib
Çoban, Eyüp
Evrensel, Türkkan
Kalkan, Ziya
Oruç, Zeynep
Derin, Sümeyra
Turna, Zeynep Hande
Bayram, Doğan
Köş, Fahriye Tuğba
Şendur, Mehmet Ali Nihat
Sever, Nadiye
Ercelep, Özlem
Seyyar, Mustafa
Kefeli, Umut
Uygun, Kazım
Özçelik, Melike
Ön, Sercan
Şanlı, Ulus Ali
Canaslan, Kübra
Ünek, İlkay Tuba
Yücel, Kadriye Bir
Özdemir, Nuriye
Yazıcı, Ozan
Güzel, Halil Göksel
Salim, Derya Kıvrak
Göksu, Sema Sezgin
Tatlı, Ali Murat
Ordu, Çetin
Selvi, Oğuzhan
Sakin, Abdullah
Büyükbayram, Mehmet Emin
Dursun, Bengü
Ürün, Yüksel
Arak, Hacı
Ağdaş, Gözde
Uğraklı, Muzaffer
Hendem, Engin
Eryılmaz, Melek Karakurt
Bilgin, Burak
Topçu, Atakan
Şimşek, Melih
Büyükşimşek, Mahmut
Akay, Büşra
Erdal, Gülçin Şahingöz
Karataş, Fatih
Alan, Özkan
Çağlayan, Melek
Kahvecioğlu, Fatma Akdağ
Demirci, Ayşe
Paksoy, Nail
Çetin, Bülent
Gümüş, Mahmut
Ak, Naziye
Aydınalp, Yasemin
Paydaş, Semra
Güven, Deniz Can
Kılıçkap, Saadettin
Sağlam, Sezer
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
title Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
title_full Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
title_fullStr Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
title_full_unstemmed Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
title_short Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
title_sort efficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: data from the turkish oncology group
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546829/
https://www.ncbi.nlm.nih.gov/pubmed/37676712
http://dx.doi.org/10.1093/oncolo/oyad257
work_keys_str_mv AT unalcaglar efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT azizyabdulmunir efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT karabulutsenem efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT tastekindidem efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT akyıldızarif efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT yasarserkan efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT yalcınsuayib efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT cobaneyup efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT evrenselturkkan efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT kalkanziya efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT oruczeynep efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT derinsumeyra efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT turnazeynephande efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT bayramdogan efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT kosfahriyetugba efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT sendurmehmetalinihat efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT severnadiye efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT ercelepozlem efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT seyyarmustafa efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT kefeliumut efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT uygunkazım efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT ozcelikmelike efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT onsercan efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT sanlıulusali efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT canaslankubra efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT unekilkaytuba efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT yucelkadriyebir efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT ozdemirnuriye efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT yazıcıozan efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT guzelhalilgoksel efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT salimderyakıvrak efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT goksusemasezgin efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT tatlıalimurat efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT orducetin efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT selvioguzhan efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT sakinabdullah efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT buyukbayrammehmetemin efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT dursunbengu efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT urunyuksel efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT arakhacı efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT agdasgozde efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT ugraklımuzaffer efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT hendemengin efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT eryılmazmelekkarakurt efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT bilginburak efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT topcuatakan efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT simsekmelih efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT buyuksimsekmahmut efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT akaybusra efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT erdalgulcinsahingoz efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT karatasfatih efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT alanozkan efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT caglayanmelek efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT kahvecioglufatmaakdag efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT demirciayse efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT paksoynail efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT cetinbulent efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT gumusmahmut efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT aknaziye efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT aydınalpyasemin efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT paydassemra efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT guvendenizcan efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT kılıckapsaadettin efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup
AT saglamsezer efficacyofcapecitabineandtemozolomideregimeninneuroendocrinetumorsdatafromtheturkishoncologygroup